About Day Zero Diagnostics
Day Zero Diagnostics provides medical devices and equipment services. It offers various whole-genome sequencing (WGS) based lab services proprietary technologies and databases of pathogens for managing healthcare-associated infection outbreaks and making clinical decisions. The company was founded in 2016 and is based in Brighton, Massachusetts.
Day Zero Diagnostics's Products & Differentiators
Research containing Day Zero Diagnostics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Day Zero Diagnostics in 4 CB Insights research briefs, most recently on Feb 15, 2022.
Expert Collections containing Day Zero Diagnostics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Day Zero Diagnostics is included in 2 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Day Zero Diagnostics Patents
Day Zero Diagnostics has filed 3 patents.
Molecular biology, Biotechnology, Molecular biology techniques, DNA, Clusters of differentiation
Molecular biology, Biotechnology, Molecular biology techniques, DNA, Clusters of differentiation
Latest Day Zero Diagnostics News
Sep 20, 2023
September 20, 2023 Day Zero Diagnostics — which seeks to harness whole-genome sequencing and AI in the fight against antibiotic-resistant infections — announced today that it has successfully wrapped up a $16M financing round. The latest round raises the Boston-based company’s venture capital funding total to $49M, coupled with over $18M in non-dilutive funding. “This funding is a strong vote of confidence in Day Zero Diagnostics’ potential to use rapid sequencing and AI to disrupt microbiology lab diagnostics,” Day Zero Diagnostics co-founder and CEO Jong Lee said in a news release. “DZD is focused on bringing an FDA-cleared diagnostic to market that will deliver the ‘holy grail’ of infectious disease diagnostics – same-day organism identification and antimicrobial susceptibility profiling directly from clinical samples, and our investors share our belief in the game-changing nature of our technology.” Day Zero Diagnostics seeks to blaze a trail with a diagnostic tool that not only identifies a myriad of bacterial and fungal pathogens but also gauges their antimicrobial susceptibility — all within an eight-hour timeframe. In contrast, present-day antimicrobial resistance tests take significantly longer, according to the company. The news release cited a 2006 study in the journal Critical Care Medicine that found that the risk of death rises by 7.6% each hour that antimicrobial administration is delayed for a person with septic shock and hypotension. Antimicrobial-resistant infections were associated with nearly 5 million deaths worldwide in 2019, according to the CDC . “No other company has solved the scientific and technical challenges required to make rapid ID and antimicrobial susceptibility profiling possible in such a short time,” said Dr. Douglas Kwon, an infectious disease physician at the Massachusetts General Hospital and a co-founder of Day Zero Diagnostics. “Physicians understand that the real enemy in treating serious systemic infections is time, and we need reliable, comprehensive diagnostic information to inform clinical decision-making far sooner than is possible today,” Kwon said in the news release . DZD will use the recent funding to complete the development of an improved Blood2Bac sample prep protocol. The enhanced protocol will enable the capture of fungi as well as bacteria, using smaller sample volumes and at a substantially lower cost, according to the company. Day Zero Diagnostics will also use the funds to accelerate the development of a prototype for its commercial system, including both the hardware system and the Keynome family of cloud-based AI algorithms to provide high-accuracy organism ID and antimicrobial susceptibility profiling. According to the company, the resulting diagnostics will allow hospitals to reduce patient stay lengths, antibiotics overuse, and patient deaths. NEWS RELEASE: S3 Connected Health joins DiMe’s team of digital health experts in their new project ‘International Regulatory Pathways’ DUBLIN, September 19, 2023 – Building on the success of the Digital Health US Regulatory Pathways, DiMe has assembled a global team of digital health experts, including S3 Connected Health, to support digital health product developers… […] Developing and commercializing a new medical device is a success worth toasting for medtech startups — but that success also makes it more likely that litigation is in their future. There are steps medtech startups can take to protect themselves down the road, said Greenberg Traurig shareholder Ginger Pigott, a litigator who defends major medical… […] Electrophysiology is “an incredibly vibrant space,” said Nikki Sidi, but access remains a challenge. Nikki Sidi, the U.S. president of Johnson & Johnson’s Biosense Webster, can look at her own company as one of those paving the way in electrophysiology (EP). Its recent milestones include multiple atrial fibrillation (AFib) mapping catheters, including ablation and mapping devices. … […] Tessy Plastics today named Stafford Frearson as the medtech supplier’s new president with former President Roland Beck becoming CEO. Frearson joined the contract manufacturer in 1997 and was promoted to his most recent role, VP of engineering, in 2018. He’s now responsible for day-to-day business operations across the plastics company’s 13 locations in the U.S.… […] NEWS RELEASE: Injection molding of thin wall cannulas — a lesson in expertise and persistence After 5 years of painstaking work, leading micro molding innovator Accumold has developed a way to micro injection mold thin wall cannulas in very high volumes. Previous to this innovative approach to production, cannulas were typically produced via an extrusion… […] As economic concerns shift from the U.S. to China, medical device manufacturers such as Medtronic and Intuitive are monitoring how procedure volumes and new policies affect their businesses. In a new note, William Blair analyst Brandon Vazquez details the exposure of those companies and four more on Medical Design & Outsourcing‘s Medtech Big 100 ranking… […] Introduction Because the security aspect of Bluetooth is greatly improved and newer technologies counter the RF interference often caused by wireless overcrowding, Bluetooth is becoming a much more trustworthy connectivity solution even in hospitals and other healthcare facilities. Hospital Settings And Its Effect on Connectivity Hospital settings are both hectic and fast-paced. The evolution of… […] Siemens Embedded Solutions address the challenge of developing medical devices through an integrated suite of software that includes: Proven operating systems and middleware Quick, easy, and secure cloud connectivity Comprehensive built-in security Best-in-class security vulnerability monitoring Pre-certified software components and quality artifacts that enable safety certification Professional services Sponsored content by Siemens The post Siemens […] An optimal design environment for connected care software development helps bring products to their peak potential of performance and safety. Siemens Connected Care solutions can help with: Software reliability via an embedded software platform built to the highest standards of cybersecurity, enabling connectivity and interoperability. Software compliance to enhance product quality, traceability and team coordination… […] Linux® is experiencing expansive growth in embedded devices across multiple industries. But the stringent requirements the healthcare industry imposes upon medical device certification and use requires extensive knowledge of using Linux around the issues of safety, security, and size of code. Sponsored content by Siemens The post Using Linux with Medical Devices FAQ appeared first […]
Day Zero Diagnostics Frequently Asked Questions (FAQ)
When was Day Zero Diagnostics founded?
Day Zero Diagnostics was founded in 2016.
Where is Day Zero Diagnostics's headquarters?
Day Zero Diagnostics's headquarters is located at 40 Guest Street, Brighton.
What is Day Zero Diagnostics's latest funding round?
Day Zero Diagnostics's latest funding round is Series B.
How much did Day Zero Diagnostics raise?
Day Zero Diagnostics raised a total of $64.33M.
Who are the investors of Day Zero Diagnostics?
Investors of Day Zero Diagnostics include National Institute of Allergy and Infectious Diseases, CARB-X, Sands Capital, Paycheck Protection Program, Small Business Innovation Research Awards and 9 more.
Who are Day Zero Diagnostics's competitors?
Competitors of Day Zero Diagnostics include IDbyDNA and 5 more.
What products does Day Zero Diagnostics offer?
Day Zero Diagnostics's products include epixact.
Compare Day Zero Diagnostics to Competitors
Hyris develops a platform that enables genetic testing of biological samples in any setting, at any time, with real-time access to results on its dedicated cloud-based software platform.
Quantumcyte is a biotechnology company. It focuses on developing single-cell analysis technologies to better understand cancer biology by personalizing solutions for the treatment of rare cancers. The company was founded in 2014 and is based in Sunnyvale, California.
Exum Instruments develops various scientific instrumentations. The instruments aid in resource play rock and fluid analysis with its mass spectrometer. Its instrument Massbox is a mobile, desktop-sized mass spectrometer that offers a range of analysis helping materials scientists and engineers in compiling data. The company was founded in 2017 and is based in Denver, Colorado.
Molsid is a biomedical company that develops fluorogenic molecular probes. It develops a technology platform for creating its custom test kits. It also develops rapid test to detect the potential presence of antimicrobial resistance (AMR) directly in primary clinical samples. The company was founded in 2018 and is based in Lyon, France.
Genecast develops cancer diagnostic products. It offers a cancer screening kit that helps to diagnose and monitor cancer through liquid biopsy using its Allele-Discriminating Priming System (ADPS) technology. The company was founded in 2016 and is based in Seoul, South Korea.
rqmicro provides rapid and quantitative microbiological test kits. It develops and markets proprietary reagents and instruments for rapid microbiological tests for water and food safety. The company was founded in 2013 and is based in Schlieren, Switzerland.